Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site

Journal of Virology

Volumn 70, Issue 7, 1996, Pages 4466-4473

  Vijh Warrier, Sujata ^a,b   Pinter, Abraham ^a   Honnen, William J ^a   Tilley, Shermaine A ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY;

ANTIBODY COMBINING SITE; ANTIGEN ANTIBODY REACTION; ARTICLE; CONFORMATIONAL TRANSITION; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; NEUTRALIZATION TESTS; PAN TROGLODYTES; PEPTIDE FRAGMENTS; TUMOR CELLS, CULTURED;

EID: 0029891454     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.7.4466-4473.1996     Document Type: Article

References (49)

1. Allaway, G. P., A. M. Ryder, G. A. Beaudry, and P. J. Maddon. 1993. Inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41. AIDS Res. Hum. Retroviruses 9:581-587.
2. Buchbinder, A., S. Karwowska, M. K. Gorny, T. Burda, and S. Zolla-Pazner. 1992. Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains. AIDS Res. Hum. Ritroviruses 8:425-427.
3. Burton, D. R., J. Pyati, R. Koduri, S. J. Sharp, G. B. Thornton, P. W. H. I. Parren, L. S. W. Sawyer, R. M. Hendry, N. Dunlop, P. L. Nara, M. Lamacchia, E. Garratty, E. R. Stiehm, V. J. Bryson, Y. Cao, J. P. Moore, D. D. Ho, and C. F. Barbas. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
4. Cavacini, L. A., C. L. Emes, J. Power, A. Buchbinder, S. Zolla-Pazner, and M. R. Posner. 1993. Human monoclonal antibodies to the V3 loop of HIV-1/gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site. J. Acquired Immune Defic. Syndr. 6:353-358.
5. Chou, J., and T. C. Chou. 1989. Dose-effect analysis with microcomputers: dose, effect, binding and kinetics, computer software for the IBM PC series (2.1 DOS, 5.25 floppy disk). Biosoft, Cambridge.
6. Chou, T. C. 1991. The median-effect principle and the combination index for quantitation of synergism and antagonism, p. 61-102. In T. C. Chou and D. C. Rideout (ed.), Synergism and antagonism in chemotherapy. Academic Press, San Diego, Calif.
7. Chou, T. C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
8. Conley, A. J., M. K. Gorny, J. A. Kessler II, L. J. Boots, M. Ossorio-Castro, S. Koenig, D. W. Lineberger, E. A. Emini, C. Williams, and S. Zolla-Pazner. 1994. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody. 447-52D. J. Virol. 68:6994-7000.
9. Conley, A. J., J. A. Kessler II, L. J. Boots, J. S. Tung, B. A. Arnold, P. M. Keller, A. R. Shaw, and E. A. Emini. 1994. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc. Natl. Acad. Sci. USA 91:3348-3352.
10. Davis, D., D. M. Stephens, C. A. Carne, and P. J. Lachmann. 1993. Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope. J. Gen. Virol. 74:2609-2517.
11. D'Souza, M. P., G. Milman, J. A. Bradac, D. McPhee, C. V. Hanson, R. M. Hendry, and collaborating investigators. 1995. Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies. AIDS 9:867-874.
12. Gartner, S., P. Markovits, D. M. Markovitz, M. H. Kaplan, R. C. Gallo, and M. Popovic. 1986. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233:215-219.
13. Gorny, M. K., J. P. Moore, A. J. Conley, S. Karwowska, J. Sodroski, C. Williams, S. Burda, L. J. Boots, and S. Zolla-Pazner. 1994. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J. Virol. 68:8312-8320.
14. Gorny, M. K., J.-Y. Xu, S. Karwowska, A. Buchbinder, and S. Zolla-Pazner. 1993. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 150:635-643.
15. 14a.Honnen, W. J., et al. Unpublished data.
16. Honnen, W. J., Z. Wu, S. C. Kayman, and A. Pinter. Potent neutralization of a macrophage-tropic HIV-1 Isolate by antibodies against the V1/V2 domain of HIV-1 gp120. In Vaccines 96, in press.
17. Javaherian, K., A. J. Langlois, G. J. LaRosa, A. T. Profy, D. P. Bolognesi, W. C. Herlihy, S. D. Putney, and T. J. Matthews. 1990. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 250:1590-1593.
18. Kayman, S. C., Z. Wu, K. Revesz, H. C. Chen, R. Kopelman, and A. Pinter. 1994. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains. J. Virol. 68:400-410.
19. Kennedy, M. S., S. Orloff, C. C. Ibegbu, C. D. Odell, P. J. Maddon, and J. S. McDougal. 1991. Analysis of synergism/antagonism between HIV-1 antibody-positive human sera and soluble CD4 in blocking HIV-1 binding and infectivity. AIDS Res. Hum. Retroviruses 7:975-981.
20. Koito, A., G. Harrowe, J. A. Levy, and C. Cheng-Mayer. 1994. Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J. Virol. 68:2253-2259.
21. Kong, X. B., Q. Y. Zhu, R. M. Ruprecht, K. A. Watanabe, J. M. Zeidler, J. W. M. Gold, B. Polsky, D. Armstrong, and T. C. Chou. 1991. Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3′-azido-3′-deoxythymidine, phosphonoformate, and 2′,3′-dideoxythymidine. Antimicrob. Agents Chemother. 35:20113-2011.
22. Laal, S., S. Burda, M. K. Gorny, S. Karwowska, A. Buchbinder, and S. Zolla-Pazner. 1994. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J. Virol. 68:4001-4008.
23. Maeda, Y., S. Matsushita, T. Hattori, T. Murakami, and K. Takasuki. 1992. Changes in the reactivity and neutralizing activity of a type-specific monoclonal antibody induced by interaction of soluble CD4 with gp120. AIDS Res. Hum. Retroviruses 8:2049-2054.
24. Matsushita, S., M. Robert-Guroff, J. Rusche, A. Koito, T. Hattori, H. Hoshino, K. Javaherian, K. Takatsuki, and S. Putney. 1988. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralization epitope. J. Virol. 62:2107-2114.
25. McKeating, J. A., J. Cordell, C. J. Dean, and P. Balfe. 1992. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type 1 gp120. Virology 191:732-742.
26. Montefiori, D. C., B. S. Graham, J. Zhou, J. Zhou, R. A. Bucco, D. H. Schwartz, L. A. Cavacini, M. R. Posner, and NIH-NIAID AIDS Vaccine Clinical Trials Network. 1993. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. J. Clin. Invest. 92:840-847.
27. Moore, J. P., V. Cao, L. Qin, Q. J. Sattentau, J. Pyati, R. Koduri, J. Robinson, C. F. Barbas, D. R. Burton, and D. D. Ho. 1995. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies. J. Virol. 69:101-109.
28. Moore, J. P., and P. L. Nara. 1991. The role of the V3 loop in HIV infection. AIDS 5(Suppl. 2):S21-S33.
29. Moore, J. P., Q. J. Sattentau, H. Yoshiyama, M. Thali, M. Charles, N. Sullivan, S. W. Poon, M. S. Fung, F. Traincard, M. Pinkus, G. Robey, J. E. Robinson, D. D. Ho, and J. Sodroski. 1993. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains. J. Virol. 67:6136-6151.
30. Moore, J. P., and J. Sodroski. 1996. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 70:1863-1872.
31. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Ruker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
32. Pinter, A., W. J. Honnen, M. E. Racho, and S. A. Tilley. 1993. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates. AIDS Res. Hum. Retroviruses 9:985-996.
33. Pinter, A., W. J. Honnen, and S. A. Tilley. 1993. Contormational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites. J. Virol. 67:5692-5697.
34. Potts, B. J., K. G. Field, Y. Wu, M. Posner, L. Cavacini, and M. White-Scharf. 1993. Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3 directed monoclonal antibodies. Virology 197:415-419.
35. Schuitemaker, H., M. Root, N. A. Kootstra, M. W. Dercksen, R. E. Y. De Goede, R. P. Van Steenwijk, J. M. A. Lange, J. K. M. Eeftink Schattenkerk, F. Miedema, and M. Tersmette. 1992. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from munocytotropic to T-cell-tropic virus populations. J. Virol. 66:1354-1360.
36. gag: identification of an epitope exposed on the surface of infected cells. J. Virol. 65:4798-4804.
37. Skinner, M. A., R. Ting, A. J. Langlois, K. J. Weinhold, H. K. Lyerly, K. Javaherian, and T. J. Matthews. 1988. Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. AIDS Res. Hum. Retroviruses 4:187-197.
38. Thali, M., C. Furman, D. D. Ho, J. Robinson, S. A. Tilley, A. Pinter, and J. Sodroski. 1992. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 66:5635-5641.
39. Thali, M., C. Furman, B. Wahren, M. Posner, D. D. Ho, J. Robinson, and J. Sodroski. 1992. Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein. J. Acquired Immune Defic. Syndr. 5:591-599.
40. Tilley, S. A., W. J. Honnen, M. Racho, M. Hilgartner, and A. Pinter. 1991. A human monoclonal antibody against the CD4 binding site of HIV-1 gp120 exhibits potent, broadly neutralizing activity. Res. Virol. 142:247-259.
41. Tilley, S. A., W. J. Honnen, M. E. Racho, T. C. Chou, and A. Pinter. 1992. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4 binding site of gp120. AIDS Res. Hum. Retroviruses 8:461-467.
42. Tilley, S. A., and A. Pinter. 1993. Human and chimpanzee monoclonal antibodies with antiviral activity against HIV-1, p. 255-287. In W. C. Koff, F. Wong-Staal, and R. C. Kennedy (ed.), AIDS research reviews, vol. 3. Marcel Dekker, Inc., New York.
43. 41a.Vijh-Warrier, S., et al. Unpublished results.
44. Vijh-Warrier, S., E. Murphy, I. Yokohama, and S. A. Tilley. 1995. Characterization of the variable regions of a chimpanzee monoclonal antibody with potent neutralizing activity against HIV-1. Mol. Immunol. 32:1081-1092.
45. Warrier, S. V., A. Pinter, W. J. Honnen, M. Girard, E. Muchmore, and S. A. Tilley. 1994. A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody. J. Virol. 68:4636-4642.
46. Westervelt, P., D. B. Trowbridge, L. G. Epstein, B. M. Blumberg, Y. Li, B. H. Hahn, G. M. Shaw, R. W. Price, and L. Ratner. 1992. Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo. J. Virol. 66:2577-2582.
47. Wu, Z., S. C. Kayman, W. Honnen, K. Revesz, H. Chen, S. Vijh-Warrier, S. A. Tilley, J. McKeating, C. Shotton, and A. Pinter. 1995. Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain. J. Virol. 69:2271-2278.
48. Wyatt, R., M. Thali, S. A. Tilley, A. Pinter, M. Posner, D. Ho, J. Robinson, and J. Sodroski. 1992. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region. J. Virol. 66:6997-7004.
49. Zhu, T., H. Mo, N. Wang, D. S. Nam, Y. Cao, R. A. Koup, and D. D. Ho. 1993. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 261:1179-1181.